12th July 2016
article written by
Cell Medica

Cell Medica acquires Delenex Therapeutics

Cell Medica acquires Delenex Therapeutics London, UK– July 12, 2016.   Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and viral infections, announced today the acquisition of Delenex Therapeutics AG, a privately held, clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics. The acquisition will […]

Read Full Article
17th June 2016
article written by
Cell Medica

Cell Medica and Baylor College of Medicine announce exclusive licensing agreement and co-development partnership to create next generation cellular immunotherapy products for the treatment of cancer

Cell Medica and Baylor College of Medicine announce exclusive licensing agreement and co-development partnership to create next generation cellular immunotherapy products for the treatment of cancer London, UK and Houston, TX – June 17, 2016 – Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and infections, announced today a ground-breaking […]

Read Full Article
24th May 2016
article written by
Cell Medica

Cell Medica Expands Management Team with Experienced Pharmaceutical Executives

Cell Medica, a leader in developing, manufacturing and marketing cellular immunotherapies for the treatment of cancer and infections, today announced key appointments to continue strengthening its senior management team. Alain Pralong, Ph.D appointed Senior Vice President, Head of Manufacturing Operations Stefanos Theoharis, Ph.D. appointed Senior Vice President and Head of Pipeline Strategy and Corporate Partnering Alain Pralong will […]

Read Full Article
18th March 2015
article written by
Cell Medica

Cell Medica granted Orphan Drug designation for novel cellular therapy; Treats first lymphoma patient in Phase II trial

Novel cellular therapy, CMD-003, granted orphan drug designation for treatment of EBV-positive non-Hodgkin lymphomas • First patient treated with CMD-003 in CITADEL Phase II clinical trial London, UK, 18 March 2015 – Cell Medica, a leading cellular immunotherapy company, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the […]

Read Full Article